Nature Reviews Immunology 15, 57–65 (2015)
In the version of this article that was originally published, the targeted epitope of lebrikizumab was listed as "IL‑4Rα" in Table 1 but this should be "IL‑13 (IL‑4Rzα‑binding epitope)". Also, for the main effects of lebrikizumab in human asthma trials, the citation of reference 44 should be reference 48. The author apologizes for these errors, which have now been corrected online.
Additional information
The online version of the original article can be found at 10.1038/nri3786
Rights and permissions
About this article
Cite this article
Fahy, J. Erratum: Type 2 inflammation in asthma — present in most, absent in many. Nat Rev Immunol 15, 129 (2015). https://doi.org/10.1038/nri3807
Published:
Issue Date:
DOI: https://doi.org/10.1038/nri3807
